Cart
Shopping cart

Alexander Reuter

Zinzino Independent Partner

Welkom! Ik ben uw onafhankelijke consulent, hier om u te begeleiden op uw gezondheidsreis.

+498031381653
gesprek Kopiëren
Press releases - dinsdag 4 juli 2017 12:00 CET

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT SECOND QUARTER 2017

Strong sales growth during the second quarter; Revenue increased 27% compared with the previous year.

Zinzino’s total revenues for the second quarter of 2017 amounted to 135.6 (107.0)* MSEK, corre­sponding to sales growth of 27% compared to the second quarter 2016.  

Accumulated for January-June 2017, total revenues amounted to 263.8 (216.8)* MSEK, corresponding to an increase of 22%.  

Sales growth is due to several factors:

- The product segment Health increased by 26% during the quarter to SEK 93.8 (74.5) million.

- Zinzino’s production unit Faun Pharma AS increased its external sales during the quarter by 149% to MSEK 19.2 (7.7).  

- Several markets showed strong growth. The new EU-markets increased by 201%, Lithuania increased by 54% during the quarter, Germany increased 53%, and the strong sales markets Swe­den and Finland increased by 50% and 34%, respectively.  

* Comparative figures adjusted per the new accounting policy regarding currency-related income and expenses.  


For more information: 

Dag Bergheim Pettersen, CEO Zinzino, Tel. +47 (0)93 22 57 00

Pictures for publication free of charge:
Marcus Tollbom, Tel. + 46 (0)70-190 03 12 

Certified Adviser:
Erik Penser, Bank Aktiebolag  

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 12.00 on 4th of July, 2017.  

Zinzino Nordic AB (publ.) is a direct sales company that operates throughout Europe and North America. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has more than 120 employees and currently trades in 33 markets across Europe and North America. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, and in Florida, USA. Zinzino is a public company and its shares are listed on Nasdaq First North. In 2016, Zinzino was recognised with the award ‘’Superföretag 2015’’ by Veckans Affärer and the ‘’Gazelle’’ award by Dagens Industri.


Tags
Zinzino